A Pilot Study of Campath-1H Induction Therapy Combined With CellCept® Therapy to Allow for a Calcineurin Inhibitor Free Regimen After Renal Transplantation
| Status: | Completed |
|---|---|
| Conditions: | Renal Impairment / Chronic Kidney Disease |
| Therapuetic Areas: | Nephrology / Urology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 6/1/2018 |
| Start Date: | January 2005 |
| End Date: | September 2007 |
The hypothesis of this study is that lymphocyte depletion by Campath-1H and rituximab will
obviate the need for long-term calcineurin inhibitors in renal transplantation. Most
successful strategies to date have relied on the use of either tacrolimus or cyclosporine.
However, the advantage of a calcineurin inhibitor free regimen may include improved renal
allograft function, a lower incidence of hypertension, diabetes, and less drug related side
effects. This is a non-randomized open-label pilot trial in 30 adult renal transplant
patients.
obviate the need for long-term calcineurin inhibitors in renal transplantation. Most
successful strategies to date have relied on the use of either tacrolimus or cyclosporine.
However, the advantage of a calcineurin inhibitor free regimen may include improved renal
allograft function, a lower incidence of hypertension, diabetes, and less drug related side
effects. This is a non-randomized open-label pilot trial in 30 adult renal transplant
patients.
Inclusion Criteria:
- renal transplant recipients
Exclusion Criteria:
- Recipients of HLA-identical living-donor renal transplants;
- multi-organ transplant;
- known hypersensitivity to Campath-1H, Rituximab, CellCept, or prednisone;
We found this trial at
1
site
University of Wisconsin In achievement and prestige, the University of Wisconsin–Madison has long been recognized...
Click here to add this to my saved trials
